Roche is trading 3.01% down at $53.53 amid broad risk-off sentiment on August 31, 2026, as renewed Middle East tensions pushed Brent crude toward $90 and elevated inflation and rate-hike concerns.

  • U.S. markets are lower.
  • No fresh company-specific negative catalyst was identified.
  • Recent developments were constructive, including positive Vabysmo SALWEEN data and the Hanmi obesity-drug licensing deal, both reported before August 31, 2026.